Trial Profile
Phase I Study on the Feasibility and Safety of Surgical Stabilizer Assisted Retinal Vein Cannulation With Ocriplasmin Infusion for Central Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Sep 2022
Price :
$35
*
At a glance
- Drugs Ocriplasmin (Primary)
- Indications Central retinal vein occlusion
- Focus Adverse reactions; Therapeutic Use
- Acronyms RVC_CRVO
- 04 Jan 2018 Status changed from recruiting to completed.
- 04 Jan 2017 Status changed from not yet recruiting to recruiting.
- 07 Jul 2016 Planned number of patients changed from 30 to 6.